UNICREDIT BANK/CALL/BRISTOL-MYERS SQUIBB/80/0.1/18.06.25 Stock UNICREDIT BANK/CALL/BRISTOL-MYERS SQUIBB/80/0.1/18.06.25
Add to a list
To use this feature you must be a member
Log inSign up

UNICREDIT BANK/CALL/BRISTOL-MYERS SQUIBB/80/0.1/18.06.25 Stock

Warrant

DE000HC7N1W5

Real-time BOERSE MUENCHEN 11:42:05 2024-06-17 am EDT
0.007 EUR -12.50% Intraday chart for UNICREDIT BANK/CALL/BRISTOL-MYERS SQUIBB/80/0.1/18.06.25
Current month-11.11%
1 month-52.94%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart UNICREDIT BANK/CALL/BRISTOL-MYERS SQUIBB/80/0.1/18.06.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors BU
More news

Quotes 5-day view

Date Price Change
24-06-17 0.007 -12.50%
24-06-14 0.008 0.00%
24-06-13 0.008 -11.11%
24-06-12 0.009 -10.00%
24-06-11 0.01 +11.11%

Real-time BOERSE MUENCHEN

Last update June 17, 2024 at 11:42 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
IssuerLogo Issuer UniCredit UniCredit
WKN HC7N1W
ISINDE000HC7N1W5
Date issued 2023-06-23
Strike 80 $
Maturity 2025-06-18 (366 Days)
Parity 10 : 1
Emission price 0.42 €
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 0.39 €
Lowest since issue 0.001 €

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2 USD
Average target price
53.19 USD
Spread / Average Target
+29.11%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant